Patrys LimitedASX: PAB

Patrys Completes Cohort 1 Dosing and Follow-Up

Sep 28, 2026 at 6:13 PM EDT · Issued by Patrys Limited via ASX

Filed with ASX · Sep 28, 2026 at 6:13 PM EDT

On 6ix: 6ix.com/news/patrys-completes-cohort-1-dosing-and-follow-up

1 29 September 2026 COHORT 1 COMPLETES DOSING AND FOLLOW-UP RLS-2202 PHASE 1A CLINICAL TRIAL HIGHLIGHTS • All Cohort 1 participants have completed dosing and the required follow-up period in the Phase 1a clinical trial of RLS-2202. • The study is designed to evaluate safety, tolerability...

View Attachment

6ix hasn’t read this filing yet.

Patrys Limited on 6ix

Earlier from Patrys

Appendix 4E Variance ReportSep 28
Annual Report - 30 June 2025Sep 28
Appendix 4G and Corporate Governance StatementSep 28
First Participants Dosed in RLS-2202 Phase 1A Clinical TrialSep 22
PAB Establishes Clinical Advisory CommitteeSep 16

Later from Patrys

Notification of cessation of securities - PABSep 30
Date of AGM and Closing Date for Director NominationsOct 5
Investor WebinarOct 5
Investor PresentationOct 12
RLS-2202 Phase 1a Trial Advances to Cohort 2Oct 21

All Patrys news releases

Follow Patrys into a list and get an email when it puts out news.

Follow Patrys